Group 1 - The cosmetics sector experienced a decline of 1.26% on December 29, with Shanghai Jahwa leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] - Key individual stock performances in the cosmetics sector included Qingdao Kingway up 1.38% and Shanghai Jahwa down 3.06% [2] Group 2 - The net outflow of main funds in the cosmetics sector was 94.94 million yuan, while retail funds saw a net inflow of 41.59 million yuan [2] - The main fund flow for Shanghai Jahwa showed a net outflow of 1.0677 million yuan, with retail funds showing a net inflow of 2.0905 million yuan [3] - Qingdao Kingway had a significant net outflow of 24.09 million yuan from main funds, while retail funds experienced a net outflow of 23.17 million yuan [3]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index declining by 1.1% from December 19 to December 26, 2025, which is weaker than the market performance [4][5]. - Lin Qingxuan is set to lead the high-end domestic essence oil sector with its upcoming IPO on December 30, 2025, planning to issue 13.9665 million H shares. The company has shown significant growth, with revenue projected to increase from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a compound annual growth rate (CAGR) of 32.7% [4][10]. - The report highlights the strong performance of Yiwang Yichuang (300792SZ) in the e-commerce agency sector, leveraging AI to enhance operational efficiency and revenue potential [11][12]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with specific indices showing declines: the Shenwan Cosmetics Index fell by 1.3%, and the Shenwan Personal Care Index decreased by 1.0% [4][5]. Key Company Developments - Lin Qingxuan's IPO is anticipated to bolster its market position, with a focus on high-end skincare products. The company has achieved a market share of 1.4% in the high-end skincare segment and ranks 10th in the anti-wrinkle product market with a 2.2% share [10]. - Yiwang Yichuang's business model is robust, with a comprehensive coverage of consumer goods categories and deep collaboration with Alibaba, positioning it well for future growth [11][12]. Market Trends - The report notes a recovery in the e-commerce agency sector, driven by increased demand for brand representation on platforms like Alibaba, with a notable rebound in traffic [12][13]. - The overall retail sales of cosmetics in China showed a growth of 4.8% year-on-year for the first 11 months of 2025, with November alone seeing a 6.1% increase, aided by promotional events [18][20]. Regulatory and Product Innovations - Jiangsu Chuangjian Medical Technology's collagen implant product received approval from NMPA, indicating ongoing innovation in the medical beauty sector [22]. - The report also mentions the investment by L'Oréal in a Chinese pharmaceutical company, marking a significant move into the skin health sector [25].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a transformation with a focus on emotional consumption and innovative product offerings, particularly in the jewelry and cosmetics sectors [6][33] - Companies like潮宏基 and毛戈平 are leveraging multi-channel strategies to enhance brand visibility and product sales, indicating a strong market presence [26][31] Summary by Sections Retail Market Overview - The retail index closed at 2462.73 points, with a weekly increase of 0.16%, underperforming the Shanghai Composite Index, which rose by 1.88% [5][15] - The retail sector has seen a year-to-date increase of 10.00%, lagging behind the Shanghai Composite Index's 18.26% rise [15][19] Company Highlights - **潮宏基**: Achieved a revenue of 62.37 billion yuan in the first three quarters of 2025, up 28.4% year-on-year, with a net profit of 3.17 billion yuan, reflecting a 0.3% increase [42] - **毛戈平**: Launched the "琉光赋活" skincare series, set to debut on January 1, 2026, focusing on high-end skincare needs [31] - **周大福**: Reported a revenue of 389.86 billion HKD for FY2026H1, a slight decrease of 1.1%, but with a net profit increase of 0.1% [39] Investment Themes - **Gold and Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending潮宏基 and老铺黄金 as key players [6][33] - **Offline Retail**: Emphasis on companies adapting to market changes, with recommendations for永辉超市 and爱婴室 [6][33] - **Cosmetics**: Highlighting brands that innovate with emotional value and safe ingredients, recommending毛戈平 and珀莱雅 [6][34] - **Medical Aesthetics**: Targeting differentiated product manufacturers and expanding medical aesthetic chains, with recommendations for爱美客 and科笛-B [6][34]

Market Overview - The cosmetics sector experienced a slight decline of 0.13% on December 26, with Qingsong Co. leading the drop [1] - The Shanghai Composite Index closed at 3963.68, up 0.1%, while the Shenzhen Component Index closed at 13603.89, up 0.54% [1] Individual Stock Performance - Marubi Biotechnology (603983) closed at 33.09, up 0.91% with a trading volume of 23,700 shares and a turnover of 78.26 million yuan [1] - Shanghai Jahwa (600315) closed at 23.17, up 0.83% with a trading volume of 32,000 shares and a turnover of 74.08 million yuan [1] - Furuida (600223) closed at 7.39, up 0.41% with a trading volume of 55,100 shares and a turnover of 40.71 million yuan [1] - Proya Cosmetics (603605) closed at 67.92, up 0.06% with a trading volume of 27,900 shares and a turnover of 20.06 million yuan [1] - Betaini (300957) closed at 40.48, down 0.59% with a trading volume of 37,100 shares and a turnover of 151 million yuan [1] - Other notable declines include Qingsong Co. (300132) down 1.57% and Jinsong New Materials (300849) down 1.55% [2] Capital Flow Analysis - The cosmetics sector saw a net outflow of 80.47 million yuan from institutional investors, while retail investors contributed a net inflow of 70.02 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Detailed Capital Flow for Selected Stocks - Furuida (600223) had a net inflow of 7.77 million yuan from institutional investors, but a net outflow of 4.35 million yuan from retail investors [3] - Huaye Fragrance (300886) saw a net inflow of 3.30 million yuan from institutional investors, while retail investors had a net outflow of 1.01 million yuan [3] - Marubi Biotechnology (603983) experienced a net inflow of 1.22 million yuan from institutional investors, with retail investors also seeing a net outflow [3] - Qingsong Co. (300132) had a significant net outflow of 1.57 million yuan from institutional investors [3]

Core Viewpoint - Peptone is widely used as a major nutrient component in culture media, promoting cell proliferation and production, with its raw materials including meat, casein, whey, gelatin, soy, yeast, and grains [2][4]. Summary by Sections 1. Peptone Market Overview - The Chinese peptone market is projected to reach 411 million yuan in 2024 and 620 million yuan by 2031, with a compound annual growth rate (CAGR) of 4.98% [4]. - Peptone serves as an important nitrogen source in microbial culture, with applications in antibiotics, vaccines, recombinant proteins, and fermentation products [8]. 2. Peptone Classification and Characteristics - Peptone is categorized into three types: animal peptone, plant peptone, and yeast peptone, each with unique properties based on the source and quality of the starting protein material [3][8]. - Animal peptone accounts for 37.01% of total consumption in 2024, with challenges in availability, cost fluctuations, and animal-source risks leading to a relative decline in demand [9]. 3. Industry Concentration Analysis - The Chinese peptone market is highly concentrated, with the top five suppliers accounting for 62.05% of sales in 2024. Angel Yeast is the largest supplier, offering a range of products across various applications [10]. 4. Peptone Industry Chain Analysis - The upstream of the peptone industry includes raw materials such as meat, casein, whey, gelatin, soy, yeast, and grains, with animal peptone being the most widely used [15][16]. - The midstream consists of manufacturing enterprises that prepare nitrogen sources from different origins, with a notable reliance on imported high-end peptone technologies [19][20]. 5. Downstream Applications - Downstream applications of peptone are concentrated in pharmaceuticals, food, cosmetics, and research, with high-end pharmaceutical companies requiring high quality and batch consistency [21]. - The market shows a diverse landscape with high-value products and a focus on process stability, indicating a robust demand across various sectors [21].

Core Viewpoint - The breakthrough of "transdermal collagen" technology by Furuida Biological Co., under the brand Kemi, marks a significant advancement in the global cosmetics science arena, showcasing China's transition from application follower to principle definer in beauty technology [3][4][10]. Group 1: Event Overview - The 79th Annual Scientific Meeting of the Society of Cosmetic Chemists (SCC) was held in New York on December 16, 2025, celebrating the 80th anniversary of the SCC, which is a historic and influential academic platform in the cosmetics science field [5]. - The conference theme "Science Reimagined" indicates the ongoing transformation within the industry, with a focus on innovative technologies from Chinese enterprises [5][9]. Group 2: Technology Breakthrough - Kemi's report highlighted a 27.5 times increase in the permeability of large molecular collagen, addressing the long-standing challenge of low absorption rates in skincare applications [3][14]. - The technology utilizes a "transdermal engine" that integrates a short peptide sequence capable of penetrating cell membranes into the collagen gene, allowing the collagen to actively enter skin cells [12]. Group 3: Scientific Validation - The efficacy of the transdermal collagen was validated through rigorous scientific methods, including Raman spectroscopy, ensuring that the technology is grounded in real physiological conditions and consumer experiences [4][20]. - Clinical trials demonstrated that after 28 days of using the Kemi Recombined Collagen Anti-Wrinkle Essence, participants experienced a 17.16% reduction in crow's feet and a 23.24% reduction in frown lines, confirming the product's effectiveness [16]. Group 4: Market Impact - Kemi's products have achieved significant market success, with the "transdermal collagen essence" becoming a top-selling item shortly after launch, reflecting consumer demand for scientifically validated anti-aging products [21][23]. - The brand's positioning as a high-end product with a clear technological narrative has resulted in a customer price point significantly above the industry average, breaking the traditional price barriers for domestic brands [21][23]. Group 5: Future Implications - The success of Kemi at the SCC signifies a new phase for Chinese beauty technology, transitioning from product and ingredient output to technology solution output, showcasing the competitive edge of Chinese enterprises in global innovation [23][24]. - The global collagen market is expected to grow at a compound annual growth rate of over 40%, indicating a shift in competition towards a focus on bioactive design, intelligent delivery technology, and scientific efficacy validation [24].

Group 1: Core Insights - Kexing Pharmaceutical is entering the rapidly growing recombinant collagen market, with a clinical trial for its type III humanized collagen product officially launched [1][2] - The recombinant collagen market in China is projected to reach 108.3 billion yuan by 2027, with a compound annual growth rate of 44.93% [1][2] - Kexing Pharmaceutical's revenue has stagnated around 1.2 billion yuan for several years, making this strategic shift a necessary move for growth [1][6] Group 2: Industry Trends - The recombinant collagen is becoming a new favorite in the medical aesthetics sector, with its market share expected to grow significantly, while hyaluronic acid's market share is declining [2][4] - Currently, only Jinbo Biotech has received approval for two type III medical devices in this space, indicating a competitive landscape that is likely to change as more companies enter [2][4] Group 3: Company Challenges - Kexing Pharmaceutical faces challenges in cash flow, with net cash flow being negative from 2022 to mid-2025, and cash reserves decreasing from 784 million yuan to 446 million yuan [4][11] - The company is also under pressure from increasing competition, with several firms, including major beauty brands, entering the recombinant collagen market [4][11] Group 4: Historical Context - Kexing Pharmaceutical and Kexing Biology share a common origin, having been established from the same foundational institutions, but have diverged significantly in their paths over the past 30 years [7][8] - Kexing Biology has faced governance issues and financial struggles, while Kexing Pharmaceutical has been criticized for its stagnant revenue and reliance on legacy products [8][11]

Summary of the Conference Call Company Overview - **Company**: 福瑞达 (Furida) - **Industry**: Cosmetics and Probiotics Key Points 1. Product Adjustments and Market Strategy - The **爱尔博士 (Aier Doctor)** probiotic series will suspend shipments by the end of 2024 due to market pricing issues, with a transition to the higher-margin **287 series** expected to complete by early 2026, alongside the launch of a new product, **王江酸 (Royal Jelly Acid)**, anticipated to drive growth in 2026. This strategy aims to protect brand integrity despite a potential short-term revenue decline of 5-10% [2][3][6] - The **颐莲 (Yilian)** brand is projected to grow rapidly in 2025, benefiting from the upgrade from **1.0 to 2.0 spray** products and effective endorsements, with expectations of double-digit growth for the year [2][5] 2. Channel Management and Inventory Control - The company has effectively addressed market pricing issues, with data indicating that the chaotic pricing phenomenon has been largely eliminated. This was achieved through a comprehensive channel management strategy, including the suspension of shipments to restore pricing integrity [2][6][7] - The company plans to increase the number of offline stores to enhance brand presence and scale, responding to the decline in online traffic benefits [8][9] 3. Product Performance and Future Expectations - The **287 series** has performed well, maintaining user retention despite price increases, and is expected to fill gaps left by declining other products [13] - The **王江酸** product, currently limited in promotion due to budget constraints, has received positive feedback and is expected to see significant growth with increased investment in 2026 [11][20] 4. Marketing and Sales Strategy - The company plans to collaborate with mid-tier influencers instead of top-tier ones, as the latter have shown declining efficiency. This shift is expected to enhance the effectiveness of marketing efforts [12] - The **颐莲** brand's marketing strategy includes a focus on high-margin non-spray products, aiming to reduce the spray product's share from 70-80% to around 65% by 2026 [15] 5. Financial Projections - The overall growth rate for **颐莲** is expected to be between 15-20% for 2025, despite a decline during the Double Eleven shopping festival being within expectations [14] - The company anticipates maintaining a gross margin of 80-85% for new products and aims to reduce costs through in-house production of raw materials and efficient packaging strategies [27] 6. Research and Development Focus - The company is prioritizing **王江酸** due to its high research barriers and broad application potential in skincare, health supplements, and medical aesthetics. This product is seen as a significant opportunity for future growth [20][21] 7. Challenges and Opportunities - The company acknowledges the challenges posed by regulatory scrutiny in the health supplement sector but is actively working to enhance its capabilities in this area, aiming to capitalize on the growing market [23][24] - The company is also exploring acquisition opportunities in the medical aesthetics and related pharmaceutical sectors, focusing on familiar fields to ensure successful integration and growth [26] 8. Internal Structure and Market Adaptation - Improvements have been made in aligning R&D with market needs, ensuring that product decisions are made collaboratively between teams to enhance market responsiveness [19] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting the company's proactive measures in addressing market challenges and its optimistic outlook for future growth.

证券之星消息，12月24日化妆品板块较上一交易日上涨0.73%，嘉亨家化领涨。当日上证指数报收于 3940.95，上涨0.53%。深证成指报收于13486.42，上涨0.88%。化妆品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300955 | 嘉亨家化 | 41.51 | 8.32% | 7.93万 | | 3.25 乙 | | 300132 | 青松股份 | 8.26 | 4.03% | 33.14万 | | 2.72亿 | | 300849 | 锦盛新材 | 16.44 | 1.54% | 3.26万 | 5332.58万 | | | 600315 | 上海家化 | 22.93 | 1.37% | - 3.05万 | 6938.73万 | | | 300740 | 水羊股份 | 21.62 | 1.22% | 8.64万 | | 1.86亿 | | 301371 | 敷尔佳 | 24.02 | 0.88% | 1.77万 | 4224.01万 | ...

Investment Rating - The industry maintains a "Recommended" rating, focusing on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][28]. Core Insights - The market performance for the week of December 15-20, 2025, showed significant gains in the retail, social services, and beauty care sectors, outperforming the overall market with increases of +6.66%, +2.66%, and +2.87% respectively [2][14]. - The total retail sales of consumer goods from January to November 2025 reached 45.61 trillion yuan, a year-on-year increase of 4%. In November alone, retail sales totaled 4.39 trillion yuan, growing by 1.3% year-on-year, which was below market expectations [3][22]. - The service consumption growth rate outpaced that of goods retail, with service retail sales increasing by 5.4% year-on-year from January to November 2025 [3][22]. Summary by Sections Market Performance - The beauty care, retail, and social services sectors ranked first, fourth, and third among 31 primary industries, respectively, during the week [2][14]. - Specific sub-sectors such as general retail, hotel and catering, and professional chains saw notable increases of +9.67%, +8.40%, and +5.06% [15]. Key Industry Data and News - The retail sales of consumer goods in November 2025 showed a modest increase, with categories like communication equipment and jewelry performing well, while automotive and home appliances faced challenges due to high base effects and subsidy reductions [3][22]. - The Ministry of Commerce initiated a two-year pilot program for new consumption models in 50 cities, aiming to stimulate consumption through various innovative approaches [3][22]. Investment Recommendations - The report suggests focusing on companies in the beauty care and new consumption sectors, recommending specific stocks such as Shangmei Co., Juzhi Biotechnology, and Marubi Biotechnology [5][28].